Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-30T21:24:51.559Z Has data issue: false hasContentIssue false
  • English
  • Français

Vancomycin Use During Left Ventricular Assist Device Support

Published online by Cambridge University Press:  02 January 2015

Rachel F. Eyler ,
Simona O. Butler ,
Paul C. Walker ,
Daryl D. DePestel ,
Martinus T. Spoor ,
Francis D. Pagani  and
Preeti N. Malani
Rachel F. Eyler
Affiliation:
Departments of Pharmacy Services, Ann Arbor, Michigan University of Michigan Health System and College of Pharmacy, Ann Arbor, Michigan
Simona O. Butler
Affiliation:
Departments of Pharmacy Services, Ann Arbor, Michigan
Paul C. Walker*
Affiliation:
Departments of Pharmacy Services, Ann Arbor, Michigan University of Michigan Health System and College of Pharmacy, Ann Arbor, Michigan
Daryl D. DePestel
Affiliation:
Departments of Pharmacy Services, Ann Arbor, Michigan University of Michigan Health System and College of Pharmacy, Ann Arbor, Michigan
Martinus T. Spoor
Affiliation:
Surgery, Section of Cardiothoracic Surgery, Ann Arbor, Michigan
Francis D. Pagani
Affiliation:
Surgery, Section of Cardiothoracic Surgery, Ann Arbor, Michigan
Preeti N. Malani
Affiliation:
Internal Medicine, Division of Infectious Diseases and Geriatric Medicine, Ann Arbor, Michigan Veterans Affairs Ann Arbor Healthcare System and Geriatric Research Education and Clinical Center, Ann Arbor, Michigan
*
University of Michigan Health System, Department of Pharmacy Services B2D301, Ann Arbor, MI 48109-0008) [email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

We reviewed the frequency and duration of vancomycin use during 93 left ventricular assist device placements. Vancomycin prophylaxis was administered for a mean duration (± standard deviation) of 10.5 ± 11 days. Empirical vancomycin use was frequent, with a mean duration (± standard deviation) of therapy of 9.8 ± 9 days (median, 8 days) given during 81 (87%) of the implantations. The most common indications for empirical vancomycin treatment were isolated leukocytosis or driveline drainage. Strategies to improve vancomycin use during left ventricular assist device support should be considered.

Type
Concise Communications
Information
Infection Control & Hospital Epidemiology , Volume 30 , Issue 5 , May 2009 , pp. 484 - 486
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Gordon, RJ, Quagliarello, B, Lowy, FD. Ventricular assist device-related infection. Lancet Infect Dis 2006;6:426–437.Google Scholar
2.Malani, PN, Dyke, DB, Pagani, FD, Chenoweth, CE. Nosocomial infections in left ventricular assist device recipients. Clin Infect Dis 2002;34:1295–1300.Google Scholar
3.Edwards, FH. The society of thoracic surgeons practice guideline series: antibiotic prophylaxis in cardiac surgery. I. Duration. Ann Thorac Surg 2006;81:397–404.Google Scholar
4.Harbarth, S, Samore, MH, Lichtenberg, D, Carmeli, Y. Prolonged antibiotic prophylaxis after cardiovascular surgery and its effect on surgical site infections and antimicrobial resistance. Circulation 2000;101:2916–2921.Google Scholar
5.Kreter, B, Woods, M. Antibiotic prophylaxis for cardiothoracic operations: meta-analysis of thirty years of clinical trials. J Thorac Cardiovasc Surg 1992;104:590–599.Google Scholar